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Despite the widespread use of antihypertensive medi-cation during pregnancy, the effects of medication on 
the fetus are unclear. Published literature is conflicting, with 
some reporting an increased incidence of preterm birth1–6 
and low birth weight,1,3–5 while others report no increased 
risk.7–9 We recently reviewed antihypertensive use during 
pregnancy and child outcomes10 and identified a lack of good 
quality studies, with many limited by self-reported medica-
tion use,1,6,11,12 small study size,13–15 and a lack of an untreated 
comparison group.1,6,11–13,16–18 An updated Cochrane review19 
also assessed trials investigating antihypertensive medication 
in mild to moderate hypertension during pregnancy and con-
cluded that there was no association between preterm birth 
or being small for gestational age following medication ex-
posure. Therefore, at present it is not clear whether there is a 
true association between adverse outcomes and antihyperten-
sive use during pregnancy.
In the United Kingdom, strict guidelines set by The 
National Institute of Care and Excellence20 are followed re-
garding the treatment of hypertension in pregnant women. 
National Institute of Care and Excellence defines hyperten-
sion as a blood pressure of 140/90 mm Hg or higher, with a 
blood pressure of 160/110 mm Hg or higher classed as severe 
hypertension. Antihypertensive agents should be given when a 
measured blood pressure of 140/90 is exceeded.
Hypertension during pregnancy can fall into several catego-
ries: chronic hypertension, indicated by a diagnosis of hyperten-
sion or antihypertensive use before 20 weeks, or if unresolved 
following birth; gestational hypertension, indicated by new onset 
diagnosis of hypertension after 20 weeks gestation, without pro-
teinuria; preeclampsia, indicated by hypertension occurring after 
20 weeks gestation, with or without proteinuria; and preeclampsia 
superimposed on chronic hypertension, indicated by pree-
clampsia in the presence of previously diagnosed hypertension.20
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Abstract—Hypertensive disorders during pregnancy are an important risk to mother and fetus, frequently necessitating 
antihypertensive treatment. Data describing the safety of in utero exposure to antihypertensive treatment is conflicting, 
with many studies suffering from significant methodological issues, such as inappropriate study design, small sample 
sizes, and no untreated control group. We conducted a retrospective cohort study using linked routinely collected 
healthcare records for 268 711 children born 2010–2014 in Scotland to assess outcomes following in utero exposure to 
antihypertensive medication. We identified a cohort of 265 488 eligible children born over the study period; of which, 2350 
were exposed to in utero antihypertensive medication, 4391 exposed to treated late-onset hypertension, and 7971 exposed 
to untreated hypertension during pregnancy. Untreated hypertension was associated with increased risk of preterm birth 
(adjusted risk ratio [aRR], 1.15 [99% CI, 1.01–1.30]), low birth weight (aRR, 2.01 [99% CI, 1.72–2.36]) and being small 
for gestational age (aRR, 1.50 [99% CI, 1.35–1.66]), while in utero antihypertensive exposure was also associated with 
preterm birth (aRR, 3.12 [99% CI, 2.68–3.64]), low birth weight (aRR, 2.23 [99% CI, 1.79–2.78]), and being small for 
gestational age (aRR, 2.13 [99% CI, 1.81–2.52]). Late-onset hypertension was also associated with preterm birth (aRR, 
2.21 [99% CI, 1.86–2.62]), low birth weight (aRR, 2.06 [99% CI, 1.74–2.43]), and being small for gestational age (aRR, 
1.90 [99% CI, 1.68–2.16]). Our results suggest that hypertension is a key risk factor for low birth weight and preterm 
birth. Although preterm birth may be associated with antihypertensive medication exposure during pregnancy, these 
associations may reflect increasing hypertension severity necessitating treatment.  (Hypertension. 2020;75:628-633. 
DOI: 10.1161/HYPERTENSIONAHA.119.13802.) • Online Data Supplement
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The aim of this study was to assess the immediate birth 
outcomes for mother and child after in utero exposure to anti-
hypertensive medication.
Materials and Methods
Because of the sensitive nature of the data collected for this study, 
requests to access the dataset from qualified researchers trained 
in human subject confidentiality protocols may be sent to the 
Information Services Division at https://www.isdscotland.org/.
This study was approved by the National Health Service Scotland 
Public Benefit and Privacy Panel for Health and Social Care on the 
18th April 2016: reference 1516-0363. Full ethical approval was 
given by the North West-Greater Manchester South Research Ethics 
Committee on the 20 April 2016: reference 16/NW/0313.
Databases
Using the Community Health Index, a unique identifier given to 
all patients who use the National Health Service in Scotland, indi-
vidual-level data from 4 Scottish healthcare databases, held by the 
Information Statistics Division, were linked. The linked databases 
used were the Scottish Morbidity Record 02 database, which col-
lects data on maternal, obstetric, and child outcomes; the Prescribing 
Information System which collects information on encashed pre-
scriptions issued by primary care and dispensed from community 
pharmacies for all Scottish residents.
Inclusion Criteria, Definitions, and Outcomes
Dispensed antihypertensive medication, excluding propranolol, were 
used as a surrogate for treated hypertension. Antihypertensive med-
ication included any of the following British National Formulary 
codes: 2.2 diuretics, 2.4 beta-adrenoceptor blocking drugs, 2.5.2 cen-
trally acting antihypertensive drugs, 2.5.5 drugs affecting the renin-
angiotensin system, and 2.6.2 calcium channel blockers. To identify 
different hypertensive presentations during pregnancy, 4 study groups 
were defined.
1. Exposure during pregnancy: All women who had a singleton 
live birth in Scotland between January 2010 and December 
2014 and who were dispensed at least one prescription for an 
antihypertensive medication during the 300 days before birth.
2. Late-onset hypertension: All women who had a singleton live 
birth in Scotland between January 2010 and December 2014 
who were dispensed at least one prescription for an antihyper-
tensive medication during the 60 days after birth, without any 
prior antihypertensive medication use. This group serves to 
identify those women who have had late-onset hypertension, 
or preeclampsia, that have not been treated throughout preg-
nancy. In the United Kingdom, women with preeclampsia will 
be started on antihypertensive therapy in secondary care, which 
is then continued in primary care after discharge. At present, 
unlike primary care prescribing, there is no national database 
of inpatient hospital prescriptions. A prescription for antihy-
pertensive medication in the 60 days following birth was, there-
fore, used as a surrogate marker for preeclampsia or late-onset 
hypertension that has not resolved after delivery.
3. Untreated hypertensive group: All women who had a singleton 
birth during the same study period, who had an International 
Classification of Diseases-Tenth Revision (ICD-10) code for 
one of the following: O10 chronic hypertension, O13 gesta-
tional hypertension, O14 preeclampsia, O15 eclampsia, O16 
unspecified hypertension, and who were not dispensed antihy-
pertensive medication at any stage during or 60 days after preg-
nancy (untreated hypertension).
4. Unexposed comparison group: All women who had a single-
ton birth during the same study period who were not dispensed 
antihypertensive medication during or 60 days following preg-
nancy, and who did not have an ICD-10 code for one of the 
following: O10 chronic hypertension, O13 gestational hyper-
tension, and O16 unspecified hypertension.
Mother-child pairs with a duplicate or missing unique identifier, mul-
tiple births, pregnancies ending with abortion, miscarriage or stillbirth, 
and mothers recorded as younger than 14 years of age were excluded 
from the study. In the United Kingdom, propranolol is not routinely 
used in the treatment of hypertension during pregnancy and is not rec-
ommended by National Institute of Care and Excellence. The most 
common cause for prescription of propranolol is anxiety and migraine, 
which was reflected by the recorded dose range of 10 to 40 mg daily 
within our cohort. We, therefore, decided that women treated with pro-
pranolol should be excluded. Women who were prescribed an ACEi 
(angiotensin-converting enzyme inhibitor) or an ARB (angiotensin II 
receptor blocker) during pregnancy were also excluded.
Four immediate birth outcomes for mother and child were stud-
ied: preterm birth, low birth weight (adjusted for gestational age), 
emergency caesarean section, and being small for gestational age. 
Preterm birth was defined as birth on or before 36 weeks gestation. 
Low birth weight was defined as a birth weight of <2500 g. Being 
small for gestational age was defined as having a birth weight below 
the 10th percentile of the population. Population percentiles were cal-
culated from the complete cohort as this represents the full Scottish 
population born 2010 to 2014.
The outcome measures were reported either as dichotomous vari-
ables (preterm birth, low birth weight, emergency caesarean section), 
or as continuous variables (gestational age, birth weight). The Scottish 
Morbidity Record 02 data set provided data on the mother’s ethnicity, 
smoking status, alcohol and illicit drug use during pregnancy, previ-
ous stillbirth parity, maternal body mass index, maternal age, diabetes 
mellitus status, and Scottish Index of Multiple Deprivation quintile 
score, which was used as a marker of area socioeconomic depriva-
tion. These variables were previously identified using a directed a-
cyclic graphs process21 and so were treated as potential confounders.
Statistical Analyses
The characteristics of mothers exposed to antihypertensive medica-
tion during pregnancy were described using appropriate summary 
statistics depending on the data type and distribution.
Where data were missing, multiple imputation chained equations 
were performed, using the MI impute function in STATA, to create 30 
data sets.22 The following variables were imputed: body mass index, 
Scottish Index of Multiple Deprivation, smoking, drug use, alcohol 
use, previous stillbirths, and parity. Body mass index was imputed by 
predictive mean matching with a K-nearest neighbors of 10, while the 
other variables were imputed by either multinomial, ordinal, or logis-
tic regression. Rubin’s rules were used to combine the results of the 
imputed data sets to provide one overall estimate, with a CI adjusted 
for uncertainty.
Poisson regressions with log links were performed for all dichot-
omous outcomes and linear regressions for continuous variables. 
Regressions were adjusted for relevant confounders as identified by 
directed acyclic graphs and then a stepwise model selection using the 
F test with a P value cutoff of 0.2. Models were adjusted for body 
mass index, Scottish Index of Multiple Deprivation, smoking, diabe-
tes mellitus, previous stillbirths, parity, illicit drug use, recorded di-
agnosis of preeclampsia during the current pregnancy, maternal age, 
and interaction terms identified. All outcomes were modeled individ-
ually and are provided in Tables 1 through 5 and Tables S2 through 
S5 in the online-only Data Supplement. Univariate and multivariate 
regression are presented with risk ratios (RR), adjusted RRs (aRR), 
and 99% CI. Analysis of data was performed in STATA MP, version 
14.1 (StataCorp).
Results
SMR 02 identified a total of 271 647 live births to 245 438 
women during 2010 to 2014. Of these, 268 711 were singleton 
live births to 226 840 women aged >14 years: 39 949 women 
had ≥2 singleton deliveries over the period. After exclusion 
of 3223 mother-child pairs prescribed propranolol and 83 
mother-child pairs prescribed an ACEI or ARB during preg-
nancy, 265 405 women-child pairs were eligible for inclusion 
in the study. Demographics of the study cohort are reported in 
the data S1, along with missing data totals.
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Exposure to Antihypertensive Medication
A total of 2350 offspring were exposed to antihypertensive 
medication during pregnancy, and 4391 offspring were born 
to women in the late-onset hypertension group. In the un-
exposed hypertensive group, a total of 7971 offspring were 
identified and 252 598 offspring in the unexposed comparison 
group. The majority of offspring were exposed to a β-blocker 
only (58.66%, 4003 children), calcium channel blockers only 
(8.18%, 558 children), or a combination of >1 antihyper-
tensive medication (20.53%, 1403 children). The remainder 
of antihypertensive exposure was a mixture of loop diuret-
ics (5.96%, 407 children), centrally acting antihypertensives 
(2.87%, 196 children), and thiazides (1.99%, 136 children).
Maternal Outcomes
A significantly increased risk of emergency caesarean section 
was associated with untreated hypertension (aRR, 1.63 [99% 
CI, 1.51–1.75]), exposure during pregnancy (aRR, 1.45 [99% 
CI, 1.27–1.64]), and late-onset hypertension (aRR, 2.16 [99% 
CI, 1.98–2.37]), compared with the unexposed comparison 
group (S2). When compared with the untreated hypertensive 
group, antihypertensive exposure during pregnancy was as-
sociated with a slight decreased risk of emergency caesarean 
section (aRR, 0.83 [99% CI, 0.71–0.96]), while late-onset 
hypertension was associated with increased risk (aRR, 1.24 
[99% CI, 1.11–1.39]; S2).
Neonatal Outcomes
Preterm Birth
Risk of preterm birth was significantly associated with un-
treated hypertension (aRR, 1.15 [99% CI, 1.01–1.30]), ex-
posure during pregnancy (aRR, 3.12 [99% CI, 2.68–3.64]), 
and late-onset hypertension (aRR, 2.71 [99% CI, 2.41–3.05]), 
compared with the unexposed comparison group (Table 1). 
When compared with the untreated hypertensive group, both 
exposure during pregnancy (aRR, 2.53 [99% CI, 2.08–3.08]) 
and late-onset hypertension (aRR, 2.24 [99% CI, 1.92–2.61]) 
were associated with increased risk of preterm birth (Table 1). 
After linear regression analysis of gestational age in weeks, 
exposure during pregnancy demonstrated the largest differ-
ence in gestational age at birth (adjusted difference in weeks, 
–1.12 [99% CI, –1.22 to –1.03]), followed by late-onset hyper-
tension (adjusted difference in weeks, –1.03 [99% CI, –1.10 
to –0.96]) and untreated hypertension (adjusted difference in 
weeks, –0.27 [99% CI, –0.33 to –0.21; Table 2).
Exposure to any single antihypertensive drug group dur-
ing pregnancy (β-blocker, calcium channel blocker, centrally 
acting antihypertensive) or >1 group of antihypertensive 
medications was significantly associated with increased risk 
of preterm birth (S3). Treatment started in any trimester was 
associated with increased risk of preterm birth (S3).
Low Birth Weight
Following adjustment for gestational age, significantly 
increased risk of low birthweight was associated with un-
treated hypertension (aRR, 2.01 [99% CI, 1.72–2.36]), ex-
posure during pregnancy (aRR, 2.23 [99% CI, 1.79–2.78]), 
and late-onset hypertension (aRR, 2.21 [99% CI, 1.86–
2.62]) compared with the unexposed comparison group 
(Table 3). There was no significant difference in the risk of 
low birth weight between the untreated hypertensive group, 
the exposed during pregnancy, and late-onset hypertension 
groups (Table 3).
After linear regression analysis of birth weight in grams, 
exposure during pregnancy demonstrated the largest dif-
ference in birth weight (adjusted difference in grams, –115 
[99% CI, –138 to –92]), followed by late-onset hypertension 
(adjusted difference in grams, –98 [99% CI, –116 to –81]) 
and untreated hypertension (adjusted difference in grams, –34 
[99% CI, –48 to –20]; Table 4). Women exposed to an antihy-
pertensive in every trimester of pregnancy or during the third 
Table 1. Preterm Birth Following In Utero Antihypertensive Exposure
Exposure Total % RR (99% CI) aRR (99% CI) RR (99% CI) aRR (99% CI)
No exposure 12 622/250 693 5.03 Reference  
Hypertensive untreated 736/7971 9.23 1.92 (1.73–2.12) 1.15 (1.01–1.30) Reference
Exposure during pregnancy 418/2350 17.79 4.09 (3.54–4.70) 3.12 (2.68–3.64) 2.13 (1.79–2.52) 2.53 (2.08–3.08)
Late-onset hypertension 801/4391 18.24 4.21 (3.80–4.67) 2.71 (2.41–3.05) 2.17 (1.88–2.50) 2.24 (1.92–2.61)
Table reports preterm birth for the untreated hypertensive, exposure during pregnancy, and late-onset hypertension groups. Model adjusted for maternal smoking, 
maternal drug misuse, diabetes mellitus, maternal ethnicity, child sex, SIMD quintile, maternal alcohol intake, maternal BMI, maternal age, preeclampsia, parity, 
caesarean section, and interactions (smoking×drugs, age×smoking, age×SIMD, age×parity, and SIMD×smoking). aRR indicates adjusted risk ratio; and RR, risk ratio.
Table 2. Gestation (Weeks) Linear Regression Results
Exposure Mean Gestation, wk Difference, wk (99% CI)
Adjusted Difference, wk 
(99% CI) Difference, wk (99% CI)
Adjusted Difference, wk 
(99% CI)
No exposure 39.36 Reference  
Untreated hypertension 38.86 –0.50 (–0.55 to –0.44) –0.27 (–0.33 to –0.21) Reference
Exposure during pregnancy 37.97 –1.39 (–1.48 to –1.29) –1.12 (–1.22 to –1.03) –0.89 (–1.02 to –0.75) –0.84 (–0.97 to –0.70)
Late onset 38.07 –1.29 (–1.38 to –1.21) –1.03 (–1.10 to –0.96) –0.78 (–0.89 to –0.67) –0.71 (–0.82 to –0.60)
Table reports difference in gestation in weeks in the untreated hypertensive, exposure during pregnancy, and late-onset hypertension groups compared to no 
exposure. Adjusted for maternal smoking, maternal drug misuse, diabetes mellitus, maternal ethnicity, child sex, SIMD quintile, maternal alcohol intake, maternal BMI, 
maternal age, preeclampsia, parity, caesarean section, and interactions (smoking×drugs, age×smoking, age×SIMD, age×parity, and SIMD×smoking).
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trimester only had a significantly increased risk of having a 
low birth weight baby (S4).
After assessment of individual drug groups, exposure to a 
β-blocker (aRR, 2.46 [99% CI, 1.75–3.45]) or >1 class of anti-
hypertensive medication (aRR, 2.45 [99% CI, 1.77–3.38]) at 
any time during pregnancy was associated with significantly 
increased risk of low birth weight (S4).
Small for Gestational Age
There was an increased risk for being born small for ges-
tational age following antihypertensive exposure during 
pregnancy (aRR, 2.13 [99% CI, 1.81–2.52]), late-onset hyper-
tension (aRR, 1.90 [99% CI, 1.68–2.16]), and untreated hy-
pertension (aRR, 1.50 [99% CI, 1.35–1.66]) when compared 
with the untreated normotensive group (Table 5). When the 
antihypertensive exposure during pregnancy and late-onset 
hypertension groups were compared with the untreated hyper-
tensive group, there was an increased risk of being small for 
gestational age (aRR, 1.33 [99% CI, 1.09–1.62]; aRR, 1.22 
[99% CI, 1.05–1.42]), respectively Table 5.
Antihypertensive exposure in trimester 3 only (aRR, 2.51 
[99% CI, 1.93–3.31]) and throughout pregnancy (aRR, 2.72 [99% 
CI, 2.06–3.58]) was associated with increased risk of being small 
for gestational age (S5). When assessing individual drug expo-
sure during pregnancy, exposure to a β-blocker only (aRR, 2.22 
[99% CI, 1.77–2.80]) or >1 mediation over the pregnancy period 
(aRR, 2.37 [99% CI, 1.86–3.03]) was associated with increased 
risk of being small for gestation (S5). Individual β-blockers were 
all associated with increased risk, with the largest increase fol-
lowing atenolol exposure (aRR, 3.83 [99% CI, 2.03–7.21]; S5).
Discussion
In this Scottish cohort of 268 711 children born between 
2010 and 2014, we demonstrated increased risk of preterm 
birth, low and extremely low birth weight, being small for 
gestational age, and emergency caesarean section following 
exposure to any antihypertensive medication during preg-
nancy. However, when compared with the untreated hyper-
tensive group, preterm birth and being small for gestational 
age remained significant. Furthermore, compared with the 
untreated hypertensive group, there was an increased risk of 
emergency caesarean section after late-onset hypertension, 
while we report a decreased risk following antihypertensive 
exposure during pregnancy. These findings suggests that a 
mix of hypertension itself, and exposure to antihypertension 
medication, is responsible for the observed increased risks 
of this study.
While there is previous literature reporting an increased 
risk of adverse outcomes, such as preterm birth and low birth 
weight following in utero antihypertensive exposure,2,4–6,17,23 
the majority of these studies were of small size, had a poor 
study design, such as inappropriate control groups, method-
ologies with residual confounding, and lacked an untreated 
hypertensive group, leading to further possible confounding. 
We have reported outcomes following in utero antihyperten-
sive exposure compared to that of an unexposed comparison 
group and an untreated hypertensive group, allowing us to dif-
ferentiate between the risks due to underlying hypertension 
and medication exposure.
We report increased risk of preterm birth in the offspring 
of those exposed during pregnancy, late-onset hypertension, 
and in the untreated hypertension groups when compared 
with the unexposed comparison group. When the untreated 
hypertensive group was used as a comparison, this associa-
tion remained for both the exposed during pregnancy and late 
onset hypertension groups. Our observations suggest that hy-
pertension per se increases the risk of preterm birth and that 
this risk increases with medication, although the association 
Table 3. Low Birth Weight Following In Utero Antihypertensive Exposure
Exposure Total % RR (99% CI) aRR (99% CI) RR (99% CI) aRR (99% CI)
No exposure 11 051/250 693 4.41 Reference  
Hypertensive untreated 797/7971 10.00 2.41 (2.18–2.66) 2.01 (1.72–2.36) Reference
Exposure during pregnancy 381/2350 16.21 4.20 (3.62–4.86) 2.23 (1.79–2.78) 1.74 (1.46–2.07) 1.05 (0.80–1.37)
Late-onset hypertension 774/4391 17.63 4.64 (4.18–5.15) 2.21 (1.86–2.62) 1.92 (1.67–2.21) 1.05 (0.85–1.30)
Table reports low birth weight for the untreated hypertensive, exposure during pregnancy, and late-onset hypertension groups. Model adjusted for maternal smoking, 
maternal drug misuse, diabetes mellitus, maternal ethnicity, child sex, SIMD quintile, maternal alcohol intake, maternal BMI, maternal age, preeclampsia, parity, 
estimated gestation, caesarean section, and interactions (smoking×drugs, age×smoking, age×SIMD, age×parity, SIMD×smoking, and gestation×diabetes mellitus). 
aRR indicates adjusted risk ratio; and RR, risk ratio.
Table 4. Birthweight (g) Linear Regression Results
Exposure
Mean Birth 
Weight, g Difference, g (99% CI)
Adjusted Difference,  
g (99% CI) Difference, g (99% CI)
Adjusted Difference,  
g (99% CI)
No exposure 3440 Reference  
Untreated hypertension 3314 –125 (–142 to –109) -34 (–48 to –20) Reference
Exposure during pregnancy 3139 –301 (–331 to –270) -115 (–138 to –92) –175 (–217 to –134) –41 (–71 to –13)
Late onset 3122 –318 (–340 to –296) –98 (–116 to –81) –191 (–225 to –156) –28 (–52 to –5)
Table reports difference in gestation in weeks in the untreated hypertensive, exposure during pregnancy, and late-onset hypertension groups compared to no 
exposure. Adjusted for maternal smoking, maternal drug misuse, diabetes mellitus, maternal ethnicity, child sex, SIMD quintile, maternal alcohol intake, maternal BMI, 
maternal age, preeclampsia, parity, estimated gestation, caesarean section, and interactions (smoking×drugs, age×smoking, age×SIMD, age×parity, SIMD×smoking, 
and gestation×diabetes mellitus).
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with medication likely reflects increasing hypertension se-
verity rather than a direct drug effect.
We observed significantly increased risk of low birth 
weight, for all exposure groups including the untreated hy-
pertensive group, compared with the unexposed comparison 
group. However, when antihypertensive exposure groups 
(during pregnancy and late-onset hypertension) were com-
pared with the untreated hypertensive group, there was no 
increased risk of low birth weight, indicating that the risk of 
low birth weight is likely due to hypertension rather than med-
ication exposure.
While several studies suffering from methodological lim-
itations2,3,5,6,23 have reported an increased risk of preterm birth 
and low birth weight associated with antihypertensive medi-
cation exposure, our results suggest that the increased risk of 
preterm birth and low birth weight is likely due to hyperten-
sion severity rather than medication exposure.
In the Scottish population, the emergency caesarean rate is 
15.9% for the general population,24 up to 40% in women with 
chronic hypertension,25 and between 30% and 60% in women 
with preeclampsia.26,27 We observed an emergency caesarean 
rate of 14.73% in our unexposed comparison group, 30.55% 
in the untreated hypertension group, 28.03% in the exposed 
group, and 37.90% in the late-onset hypertension group, 
which are in line with published levels thus strengthening our 
group selection.
Strengths of the Study
The use of Scotland-wide data sets, containing routinely col-
lected healthcare data, permitted identification a large, non-
selective cohort covering all eligible pregnancies in Scotland 
over a 5-year period. This approach obviated the possibility of 
selection or recruitment bias and provided sufficient statistical 
power to undertake sub-group analyses. Linkage of routinely 
collected healthcare data for offspring provided information 
on a wide range of child outcomes from birth to 30-month 
follow-up. Using dispensing data to determine drug exposure 
rather than issued prescriptions or self-reported medication 
use reduced the risk of reporting bias.
Limitations of Study
Several assumptions were made in this study: use of an anti-
hypertensive medication was solely for treatment of hyper-
tension; women who did not have an ICD-10 code recorded 
in the Scottish Morbidity Record 02 data and who did not 
have antihypertensive medication dispensed were normoten-
sive; and exposure following birth was indicative of late-onset 
hypertension or preeclampsia. As detailed clinical information 
was not available, we could not identify the severity of hy-
pertension in affected women. While we cannot say whether 
hypertension was severe, we can use antihypertensive medica-
tion use as a proxy in this case, particularly if women are on 
>1 antihypertensive medication during pregnancy, indicating a 
greater need for blood pressure control. Due to the number of 
outcomes assessed, multiple testing was a potential issue. This 
was dealt with by increasing the threshold of significance and 
using 99% CIs. However, this poses a further limitation in that 
we may have missed significant results that do not meet these 
strict significance levels. Furthermore, due to the data-linkage 
cohort study design, it is not possible to guarantee coherence 
to medication regimes. We have attempted to limit this con-
founding by only using dispensed prescription data generated 
following the woman obtaining the medication from a phar-
macy, rather than the prescription issued by a doctor.
Perspectives
We demonstrated an increased risk of preterm birth, low birth 
weight, small for gestational age, and emergency caesarean 
section in the offspring of both treated and untreated hyper-
tensive women. Rather than treatment with antihypertensive 
medication, hypertension severity may dictate the risk of pre-
term birth, while underlying hypertension may be the cause of 
low birth weight and small for gestational age.
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What Is New?
•	This is the first Scotland-wide study of blood pressure medications taken 
in pregnancy and the effects on the baby.
What Is Relevant?
•	Women who had high blood pressure requiring treatment during preg-
nancy were more likely to deliver earlier. All women with hypertension, 
regardless of whether treated or untreated, had a similar risk of having 
low birth weight babies.
•	Emergency caesarean section was decreased in those treated with med-
ication during pregnancy compared to those untreated.
Summary
This is the first Scotland-wide study looking at blood pressure 
medication taken during pregnancy. High blood pressure, whether 
treated or untreated, was associated with a range of poorer out-
comes in the child.
Novelty and Significance
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